ABPI appoints new commercial head
This article was originally published in Scrip
The Association of the British Pharmaceutical Industry (ABPI) has appointed Richard Torbett as Executive Director – Commercial UK. Before joining the ABPI, Mr Torbett held the role of chief economist and director of strategy at the European Federation of Pharmaceutical Industries and Associations (EFPIA). Prior to this, he spent six years working at Pfizer, where he was senior director and head of international affairs.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.